Drug Trial Radar · NCT04222972
A Study of Pralsetinib Versus Standard of Care for First-Line Treatment of Advanced Non-Small Cell Lung Cancer (NSCLC)
Last checked: Nov 19, 2026Latest source record: Mar 5, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Terminated
Enrollment
223
Actual
Start
Jul 24, 2020
Primary completion
Jan 27, 2025
Study completion Jan 27, 2025
Sponsor
- Lead sponsor
- Hoffmann-La RocheRoche (Genentech) (RHHBY)
- Sponsor type
- Industry
- First posted
- Jan 10, 2020
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is an international, randomized, open-label, Phase 3 study designed to evaluate whether the potent and selective RET inhibitor, pralsetinib, improves outcomes when compared to a platinum chemotherapy-based regimen chosen by the Investigator from a list of standard of care treatments, as measured primarily by progression free survival (PFS), for participants with RET fusion-positive metastatic NSCLC who have not previously received systemic anticancer therapy for metastatic disease.
Conditions
- RET-fusion Non Small Cell Lung Cancer
- Lung Neoplasm
- Carcinoma, Non-Small-Cell Lung
- Respiratory Tract Neoplasms
- Thoracic Neoplasms
- Neoplasms by Site
- Neoplasms
- Lung Diseases
- Respiratory Tract Disease
- Carcinoma, Bronchogenic
- Bronchial Diseases
- Head and Neck Neoplasms
- Adenocarcinoma
- Carcinoma
- Neoplasms by Histologic Type
- Neoplasms, Germ Cell and Embryonal
- Neoplasms, Nerve Tissue
Interventions
PralsetinibDrug
Administered orally
CarboplatinDrug
Administered IV
CisplatinDrug
Administered IV
PemetrexedDrug
Administered IV
PembrolizumabDrug
Administered IV
GemcitabineDrug
Administered IV
PaclitaxelDrug
Administered IV
Nab-PaclitaxelDrug
Administered IV
Primary outcomes
What the sponsor says the trial is designed to measure.
- Arm A vs Arm B: Treatment Period: Progression-free Survival (PFS)Time frame: Up to approximately 50 months
Locations
74 sites in 22 countries. Site status is shown where the registry gives one.
Hospital Britanico
Buenos Aires, Argentina
Centro Oncologico Riojano Integral (CORI)
La Rioja, Argentina
Royal North Shore Hospital
St Leonards, New South Wales, Australia
UZ Antwerpen
Edegem, Belgium
Hospital Sao Lucas - PUCRS
Porto Alegre, Rio Grande do Sul, Brazil
Hospital A. C. Camargo
São Paulo, São Paulo, Brazil
Clinica CIMCA
San José, Costa Rica
Institut Bergonie CLCC Bordeaux
Bordeaux, France
Hôpital Ambroise Paré - Boulogne-Billancourt
Boulogne-Billancourt, France
Hôpital Louis Pradel, Hospices Civils de Lyon
Bron, France
CHRU Lille Service de Pneumologie et Oncologie Thoracique
Lille, France
Institut Paoli Calmettes
Marseille, France
Hopital Bichat Claude Bernard
Paris, France
Hopital Tenon
Paris, France
Hopital de Pontchaillou
Rennes, France
Ico Rene Gauducheau
Saint-Herblain, France
CHU Strasbourg - Nouvel Hopital Civil
Strasbourg, France
CHU de Toulouse - Hôpital Larrey
Toulouse, France
Institut Gustave Roussy
Villejuif, France
Universitätsklinikum Carl Gustav Carus, Medizinische Klinik I, Pneumologie MK1-A13
Dresden, Germany
Asklepios-Fachkliniken Muenchen-Gauting
Gauting, Germany
Pius-Hospital
Oldenburg, Germany
Leopoldina-Krankenhaus Medizinische Klinik II
Schweinfurt, Germany
Klinik Schillerhöhe
Stuttgart, Germany
St. James Hospital
Dublin, Ireland
Ospedale Clinicizzato SS Annunziata
Chieti, Abruzzo, Italy
IRCCS Giovanni Paolo II Istituto Oncologico
Bari, Apulia, Italy
Istituto Nazionale per lo Studio e la Cura dei Tumori Fondazione G. Pascale
Naples, Campania, Italy
Ospedale Provinciale Santa Maria Delle Croci
Ravenna, Emilia-Romagna, Italy
Istituto Nazionale Tumori Regina Elena
Rome, Lazio, Italy
AZ. Ospedaliera San Giovanni - Addolorata
Rome, Lazio, Italy
Irccs Ospedale San Raffaele
Milan, Lombardy, Italy
Fondazione IRCCS Istituto Nazionale dei Tumori
Milan, Lombardy, Italy
Istituto Europeo Di Oncologia
Milan, Lombardy, Italy
Azienda Ospedaliera Universitaria Pisana - Ospedale Cisanello
Pisa, Tuscany, Italy
IOV - Istituto Oncologico Veneto - IRCCS
Padova, Veneto, Italy
A.O.U. INTEGRATA DI VERONA-Ospedale Civile Maggiore Borgo Trento
Verona, Veneto, Italy
Kyushu University Hospital
Fukuoka, Japan
National Hospital Organization Himeji Medical Center
Hyōgo, Japan
Osaka International Cancer Institute
Osaka, Japan
Showing 40 of 74 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.